Althought CD4+ T cells percentages and CD4/CD8 T cell ratio were equivalent in both groups before HIV-1 infection and VX-765 treatment, percentages of circulating CD4+ T cells and CD4/CD8 T cell ratio at day 22 post-infection in the VX-765-treated group were slightly higher (p<0.05; Figure 5A and B). The gene discussed is CD8A; the disease is HIV-1 infection.